Bioventus (NYSE:BVS) Releases FY 2025 Earnings Guidance

Bioventus (NYSE:BVS) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 0.640-0.680 for the period, compared to the consensus estimate of 0.550. The company issued revenue guidance of $560.0 million-$570.0 million, compared to the consensus revenue estimate of $554.8 million.

Analyst Upgrades and Downgrades

Separately, JPMorgan Chase & Co. raised Bioventus from an “underweight” rating to a “neutral” rating and lifted their price target for the stock from $12.00 to $13.00 in a research note on Tuesday, December 17th.

Bioventus Trading Down 6.8 %

Shares of BVS stock opened at $10.07 on Thursday. The firm has a 50-day moving average price of $10.12 and a 200 day moving average price of $11.01. Bioventus has a twelve month low of $3.90 and a twelve month high of $14.38. The company has a market capitalization of $817.23 million, a price-to-earnings ratio of -16.51 and a beta of 0.86. The company has a current ratio of 1.41, a quick ratio of 0.99 and a debt-to-equity ratio of 1.85.

Insider Activity

In other news, SVP Katrina J. Church sold 2,535 shares of the company’s stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $10.53, for a total transaction of $26,693.55. Following the completion of the transaction, the senior vice president now owns 47,264 shares of the company’s stock, valued at $497,689.92. This represents a 5.09 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Anthony D’adamio sold 4,380 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $10.19, for a total transaction of $44,632.20. Following the transaction, the senior vice president now directly owns 118,178 shares of the company’s stock, valued at approximately $1,204,233.82. This represents a 3.57 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 52,932 shares of company stock valued at $512,511 in the last 90 days. 32.90% of the stock is currently owned by insiders.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.